Related Experiment Video
Updated: Feb 21, 2026
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Insight into the Selectivity of the G7-18NATE Inhibitor Peptide for the Grb7-SH2 Domain Target
Gabrielle M Watson1, William A H Lucas1, Menachem J Gunzburg1
1Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
Abstract:
Growth factor receptor bound protein 7 (Grb7) is an adaptor protein with established roles in the progression of both breast and pancreatic cancers. Through its C-terminal SH2 domain, Grb7 binds to phosphorylated tyrosine kinases to promote proliferative and migratory signaling. Here, we investigated the molecular basis for the specificity of a Grb7 SH2-domain targeted peptide inhibitor. We identified that arginine 462 in the BC loop is unique to Grb7 compared to Grb2, another SH2 domain bearing protein that shares the same consensus binding motif as Grb7. Using surface plasmon resonance we demonstrated that Grb7-SH2 binding to G7-18NATE is reduced 3.3-fold when the arginine is mutated to the corresponding Grb2 amino acid. The reverse mutation in Grb2-SH2 (serine to arginine), however, was insufficient to restore binding of G7-18NATE to Grb2-SH2. Further, using a microarray, we confirmed that G7-18NATE is specific for Grb7 over a panel of 79 SH2 domains, and identified that leucine at the βD6 position may also be a requirement for Grb7-SH2 binding. This study provides insight into the specificity defining features of Grb7 for the inhibitor molecule G7-18NATE, that will assist in the development of improved Grb7 targeted inhibitors.
Insights
Growth factor receptor bound protein 7 (Grb7) is crucial in cancer progression. Researchers identified specific amino acids in Grb7’s SH2 domain that confer unique binding to an inhibitor peptide, aiding future drug development.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Background:
- Growth factor receptor bound protein 7 (Grb7) is an adaptor protein implicated in breast and pancreatic cancer progression.
- Grb7 utilizes its C-terminal SH2 domain to bind phosphorylated tyrosine kinases, driving proliferative and migratory signaling.
Purpose of the Study:
- To investigate the molecular basis for the specificity of a Grb7 SH2-domain targeted peptide inhibitor, G7-18NATE.
- To identify key amino acid residues in Grb7 responsible for its unique binding interactions with G7-18NATE.
Main Methods:
- Site-directed mutagenesis was employed to alter specific amino acids within the Grb7 and Grb2 SH2 domains.
- Surface plasmon resonance (SPR) was used to quantify the binding affinity between mutant SH2 domains and the G7-18NATE peptide.
- Microarray analysis was performed to assess the specificity of G7-18NATE against a panel of 79 SH2 domains.
Main Results:
- Mutation of arginine 462 in the Grb7 SH2 domain's BC loop to the corresponding Grb2 amino acid reduced G7-18NATE binding by 3.3-fold.
- The reverse mutation in Grb2 SH2 was insufficient to restore G7-18NATE binding, highlighting the importance of Grb7's unique arginine.
- G7-18NATE demonstrated specificity for Grb7 over 79 other SH2 domains, with leucine at the βD6 position also suggested as a binding requirement.
Conclusions:
- Arginine 462 and potentially leucine at βD6 are key determinants of Grb7 SH2 domain specificity for the inhibitor G7-18NATE.
- Understanding these specificity features is crucial for the rational design of improved Grb7-targeted cancer therapeutics.
